CytoSorbents Corp. (NSDQ:CTSO) and Fresenius Medical Care (NYSE:FMS) said today that the 2 companies have expanded the terms of their partnership and added a co-marketing agreement for the CytoSorb blood adsorber in countries where the therapy is available. According to the 3-year agreement, CytoSorbents extended Fresenius’ exclusive distributorship of the device for critical care applications in […]
CytoSorbents Corp. (NSDQ:CTSO) shares jumped 9% to $5.35 apiece today after the company reported that it landed a permanent reimbursement procedure code for its CytoSorb therapy in Germany. The Monmouth Junction, N.J.-based company developed its blood purification therapy to treat inflammation in critically-ill patients and for use during cardiac surgery. CytoSorb is an extracorporeal cytokine […]
CytoSorbents said today that it’s entering the Iranian market with its CytoSorb adsorber through an exclusive distribution agreement with Armaghan Salamat Kish Group. CytoSorb is designed to reduce excessive levels of inflammatory mediators in cardiac surgery and critically ill patients, the Monmouth Junction, N.J.-based company said. “We are pleased that Armaghan Salamat Kish will be working with us to […]
Terumo Corp. (TYO:4543) said today it inked a strategic partnership deal with CytoSorbents to commercialize its CytoSorb blood purification adsorber for cardiac surgery applications. New Jersey-based CytoSorbents said its CytoSorb adsorber is designed to reduce excessive levels of inflammatory mediators in cardiac surgery and critically ill patients. “Our collaboration with CytoSorbents enables us to offer […]
CytoSorbents (OTC:CTSO) said today it’s dropping its pursuit of the FDA’s fast-track Expedited Access Pathway for its CytoSorb for treating sepsis. The decision came after meeting with the FDA’sCenter for Devices and Radiological Health and Center for Drug Evaluation and Research in which the company came to the conclusion that “there would be no significant time […]
The FDA approved two cardiac ablation catheters made by St. Jude Medical Inc. (NYSE:STJ).
The devices are designed to treat cardiac arrhythmias through the targeted scaring of heart tissue to block abnormal electrical signals that would contribute to irregular heart beats.